Prime Capital Investment Advisors LLC Has $2.24 Million Stock Holdings in Danaher Corporation $DHR

Prime Capital Investment Advisors LLC cut its stake in shares of Danaher Corporation (NYSE:DHR) by 21.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,349 shares of the conglomerate’s stock after selling 3,103 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Danaher were worth $2,242,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of DHR. Nuveen LLC acquired a new position in Danaher during the first quarter valued at approximately $833,941,000. Invesco Ltd. lifted its position in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after buying an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. lifted its position in shares of Danaher by 290.6% in the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after buying an additional 1,072,617 shares during the last quarter. Generation Investment Management LLP lifted its position in shares of Danaher by 33.2% in the first quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock valued at $651,515,000 after buying an additional 791,662 shares during the last quarter. Finally, Parnassus Investments LLC lifted its position in shares of Danaher by 23.3% in the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock valued at $784,745,000 after buying an additional 722,636 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.20% of the stock is currently owned by company insiders.

Danaher Stock Performance

NYSE:DHR opened at $208.63 on Wednesday. The stock has a market cap of $149.39 billion, a P/E ratio of 44.39, a PEG ratio of 3.02 and a beta of 0.77. The stock has a 50 day simple moving average of $200.40 and a 200 day simple moving average of $197.32. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.41.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter last year, the company earned $1.72 EPS. The company’s revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is 27.23%.

Analyst Ratings Changes

A number of research firms have recently issued reports on DHR. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Danaher in a research report on Saturday, September 27th. Evercore ISI raised their price objective on Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research report on Tuesday. Robert W. Baird raised their price objective on Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a research report on Friday, July 18th. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research report on Friday, June 27th. Finally, Barclays reissued an “overweight” rating and set a $225.00 price target (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Seventeen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $246.74.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.